These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


857 related items for PubMed ID: 9532406

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
    Cunningham RS.
    Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB.
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
    Navari RM.
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):715-24. PubMed ID: 15485308
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics.
    Hsu ES.
    Am J Ther; 2010 Oct; 17(5):476-86. PubMed ID: 20844345
    [Abstract] [Full Text] [Related]

  • 11. Clinical practice guidelines on antiemetics in oncology.
    Aranda Aguilar E, Constenla Figueiras M, Cortes-Funes H, Diaz-Rubio García E, Gascon Vilaplana P, Guillém V, Martin-Algarra S.
    Expert Rev Anticancer Ther; 2005 Dec; 5(6):963-72. PubMed ID: 16336087
    [Abstract] [Full Text] [Related]

  • 12. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P, Manusirivithaya S, Tangjitgamol S, Thavaramara T, Sukwattana P.
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.
    Bruntsch U, Drechsler S, Eggert J, Gosse H, Ukena D, Imhoff W, Faerber L.
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):7-11. PubMed ID: 9113120
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [New developments in the treatment of nausea and vomiting caused by chemotherapy].
    de Wit R, van Alphen MM.
    Ned Tijdschr Geneeskd; 2003 Apr 12; 147(15):690-4. PubMed ID: 12722531
    [Abstract] [Full Text] [Related]

  • 20. A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis.
    Madej G, Krzakowski M, Pawinski A, Lasota W, Rogowski W, Skoneczna I.
    Semin Oncol; 1994 Oct 12; 21(5 Suppl 9):3-6. PubMed ID: 9113119
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 43.